Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer

(2012) Takeshi Sasaki et al.   ENDOCRINE-RELATED CANCER

Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: Clinical application and validation

(2012) Yasuhide Kitagawa et al.   INTERNATIONAL JOURNAL OF UROLOGY

Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy

(2011) Shu-Pin Huang et al.   PROSTATE

Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer

(2010) S. Hori et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

(2009) Toni K. Choueiri et al.   CANCER

Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy

(2009) Matthew R. Cooperberg et al.   JOURNAL OF CLINICAL ONCOLOGY

EAU Guidelines on Prostate Cancer

(2007) Axel Heidenreich et al.   EUROPEAN UROLOGY